Press Release – New York, NY – July 16, 2020 – Sichenzia Ross Ference LLP announced that it represented Equillium, Inc. (NASDAQ: “EQ”), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, in an At-The-Market Offering (“ATM”), whereby Equillium may sell up to $150 million of common stock from time-to-time. Jefferies LLC is acting as the sales agent in connection with the ATM.
The shares were registered on Equillium’s Registration Statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on November 25, 2019 (File No. 333-234683) and the prospectus supplement relating to the ATM dated July 14, 2020.
The Sichenzia Ross Ference LLP team was led by partners Marc J. Ross and James M. Turner.
Visit SRFC's LinkedIn page
- Sichenzia Ross Ference Carmel LLP Represents ThinkEquity in $2.5 Million Public Offering of CEL-SCI Corporation - March 19, 2025
- Sichenzia Ross Ference Carmel Names Evan Cappelli as its Corporate and Securities Department Managing Partner - March 18, 2025
- Sichenzia Ross Ference Carmel LLP Represents D. Boral Capital in $15 Million Private Placement Offering of Plus Therapeutics - March 4, 2025
